Several features associated with cachexia, such as loss of muscle mass, skeletal muscle expression of Cathepsin L and LC3, as well as markers of intestinal permeability and immune function, showed slight improvements following synbiotic administration. The gene discussed is MAP1LC3A; the disease is Cachexia.